The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.

•Individualised sunitinib therapy is feasible, safe and an effective method to manage toxicity.•There was a wide interindividual variation in the optimal sunitinib dose and treatment duration.•About 18.5% of patients were dose escalated above the standard 50 mg dose.•Fewer patients were dose reduced or discontinued therapy due to toxicity vs. standard dosing.•With one of the best efficacy seen for oral vascular endothelial growth factor drugs with no decline in quality of life on therapy.